1. A neutralizing antibody prevents postfusion transition of measles virus fusion protein.
- Author
-
Zyla DS, Della Marca R, Niemeyer G, Zipursky G, Stearns K, Leedale C, Sobolik EB, Callaway HM, Hariharan C, Peng W, Parekh D, Marcink TC, Diaz Avalos R, Horvat B, Mathieu C, Snijder J, Greninger AL, Hastie KM, Niewiesk S, Moscona A, Porotto M, and Ollmann Saphire E
- Subjects
- Humans, Protein Conformation, Antibodies, Neutralizing immunology, Antibodies, Neutralizing chemistry, Measles virus immunology, Measles virus chemistry, Cryoelectron Microscopy, Viral Fusion Proteins immunology, Viral Fusion Proteins chemistry, Antibodies, Monoclonal immunology, Antibodies, Monoclonal chemistry, Antibodies, Viral immunology, Antibodies, Viral chemistry
- Abstract
Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in the general population declines and as populations of immunocompromised individuals, who cannot be vaccinated, increase. There are no approved therapeutics for MeV. Neutralizing antibodies targeting viral fusion are one potential therapeutic approach but have not yet been structurally characterized or advanced to clinical use. We present cryo-electron microscopy (cryo-EM) structures of prefusion F alone [2.1-angstrom (Å) resolution], F complexed with a fusion-inhibitory peptide (2.3-Å resolution), F complexed with the neutralizing and protective monoclonal antibody (mAb) 77 (2.6-Å resolution), and an additional structure of postfusion F (2.7-Å resolution). In vitro assays and examination of additional EM classes show that mAb 77 binds prefusion F, arrests F in an intermediate state, and prevents transition to the postfusion conformation. These structures shed light on antibody-mediated neutralization that involves arrest of fusion proteins in an intermediate state.
- Published
- 2024
- Full Text
- View/download PDF